About 51,100 results
Open links in new tab
GSK's Arexvy excels in two trials for at-risk patients age 18-49
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, …
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine…
Arexvy Looks Promising for RSV Protection in Younger At-Risk …
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK ...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Real-World Study Confirms RSV Vaccine's, Arexvy and Abrysvo, …
GSK Announces New Positive Data For RSV Vaccine, Arexvy In …
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine…
RSV Vaccine Guidance for Older Adults | RSV | CDC